HeartBeam (Nasdaq:BEAT) today announced that a study of its synthesized 12-lead electrocardiogram (ECG) met its clinical ...

A 12-lead ECG is obtained. Figure 1. Courtesy of Philip J. Podrid, MD. The correct diagnosis is sinus rhythm and acute transmural myocardial infarction (Figure 2). Figure 2. Courtesy of Philip J.

HeartBeam rolled out an application for its 12-lead ECG synthesis software to the FDA, based on the data from the study.

Every year, some mothers die after giving birth due to heart problems, and many of these deaths could be prevented. The ...

The study evaluated the mean difference in ECG intervals and amplitudes between HeartBeam's synthesized 12-lead ECG and simultaneously collected standard 12-lead ECG that are important in assessing ...

Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.

HeartBeam (NASDAQ: BEAT) announced that its synthesized 12-lead ECG technology met clinical endpoints in the VALID-ECG pivotal study, achieving a 93.

Milestone results formed the basis of HeartBeam’s 12-lead ECG synthesis software application submitted to FDA in January 2025 SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam, Inc., (NASDAQ: BEAT), a ...

SANTA CLARA, Calif., April 29, 2025--(BUSINESS WIRE)--HeartBeam, Inc., (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights ...